Immunohistochemical Expression of Retinoblastoma Gene Product and p53 Protein in Transitional Cell Carcinoma of the Urinary Bladder and its Relationship to Different Clinicopathological Parameters

Alaa Yahya; Zina A. Rajab Alhamadani; Mohanad Mundher

doi:10.3889/oamjms.2021.6559

Authors

Alaa Yahya Department of Pathology, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0001-7225-1851
Zina A. Rajab Alhamadani Laboratories Teaching, Medical City, Ministry of Health, Baghdad, Iraq
Mohanad Mundher Department of Pathology, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0003-2673-7169

DOI:

https://doi.org/10.3889/oamjms.2021.6559

Keywords:

Bladder cancer, p53, pRb, Transitional cell carcinoma and immunohistochemistry

Abstract

BACKGROUND: Carcinoma of urinary bladder is one of the most common malignancies worldwide and constitutes a major health problem. Multiple risk factors are associated with this tumor and its prognosis will depend on different clinicopathological parameters. Over expression of P53 protein and mutant Rb gene is associated with more aggressive clinical and histopathological features of the tumor such as advanced stage and higher grade.

AIM: The immunohistochemical expression of Rb gene and P53 gene will be assessed through their protein products in transitional cell carcinoma (TCC) of the urinary bladder and then will be correlated with other well-known risk factors and prognostic parameters of bladder TCC, such as grading, tumor size, smoking, alcohol drinking, and family history.

METHODS: Patients were recruited from the uro-surgical department/Surgical Subspecialties Teaching Hospital during the period from November 2020 through April 2021. In this study, patients enrolled were those suspected to have bladder carcinoma. The work up included a full history and clinical examination. Surgical samples were taken from the patients for histopathological evaluation; the study’s samples represented either endoscopic cup biopsy, transurethral resection of the tumor, or radical cystectomy. Sections obtained from these samples were stained with the conventional hematoxylin and eosin stain. Then, immunohistochemical staining for P53 and pRB was applied only for patients diagnosed with TCC.

RESULTS: The differences between low-grade and high-grade tumors regarding pRb percentage score were statistically significant (p = 0.026), but were not significant regarding the intensity score (p = 0.094). There were significant correlations between tumor stage and both pRb intensity and percentage scores (p = 0.044 and 0.042, respectively). Differences between low-grade and high-grade tumors regarding p53 intensity score were significant (p = 0.022). The differences between low-grade and high-grade tumors regarding p53 percentage score were significant (p = 0.049). The differences between different tumor stages regarding p53 intensity score were significant (p = 0.018). The differences between different tumor stages regarding P53 percentage score were significant (p = 0.019).

CONCLUSIONS: Tumor’s grade was found to be correlated with the tumor stage with no correlation with the age, gender, smoking, family history of TCC, history of urinary tract infection, bladder stones, nor the recurrence of the tumor. The pRb intensity and the percentage scores were correlated to each other and to tumor’s grade and stage, except for the pRb intensity which showed no correlation with the tumor’s grade. The P53 intensity and percentage scores were correlated to each other and also to tumor’s grade and stage, so that P53 is over-expressed in tumors with higher grade and stage.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10-30. https://doi.org/10.3322/canjclin.55.1.10 PMid:15661684 DOI: https://doi.org/10.3322/canjclin.55.1.10

Reddy PV. Prognostic value of P53 nuclear overexpression in bladder cancer. Int J Med Res Rev. 2017;5(6):569-70. DOI: https://doi.org/10.17511/ijmrr.2017.i06.05

Crow P, Ritchie AW. National and international variation in the registration of bladder cancer. BJU Int. 2003;92(6):563-6. https://doi.org/10.1046/j.1464-410x.2003.04421.x PMid:14511034 DOI: https://doi.org/10.1046/j.1464-410X.2003.04421.x

Pernick N. p53. Available from: https://www.pathologyoutlines.com/topic/stainsp53.html. [Last accessed on 2021 Mar 13].

Goussia AC, Αlexandra PB, Antonia C, Panagiotis K, Panagiotis K, John KE, et al. Alterations of p53 and Rb pathways are associated with high proliferation in bladder urothelial carcinomas. Anticancer Res. 2018;38(7):3985-88. https://doi.org/10.21873/anticanres.12685 PMid:29970521 DOI: https://doi.org/10.21873/anticanres.12685

Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer. 2001;1(3):222-31. https://doi.org/10.1038/35106065 PMid:11902577 DOI: https://doi.org/10.1038/35106065

Marr BP, Hung C, Gobin YP, Dunkel IJ, Brodie SE, Abramson DH. Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: Effect of orbitovascular anatomy. Arch Ophthalmol. 2012;130(2):180-5. https://doi.org/10.1001/archophthalmol.2011.386 PMid:22332209 DOI: https://doi.org/10.1001/archophthalmol.2011.386

Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268-71. https://doi.org/10.1001/archophthalmol.2012.1983 PMid:23044940 DOI: https://doi.org/10.1001/archophthalmol.2012.1983

Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078-83. https://doi.org/10.1136/bjophthalmol-2011-301450 PMid:22694968 DOI: https://doi.org/10.1136/bjophthalmol-2011-301450

Liukkonen T, Lipponen P, Raitanen M, Kaasiner E, Ala-Opas M, Rajala P, et al. Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Urol Res. 2000;28(5):285-92. https://doi.org/10.1007/s002400000116 PMid:11127704 DOI: https://doi.org/10.1007/s002400000116

Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, et al. Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell-cycle associated proteins, cell proliferation and clinical outcome. Int J Cancer. 2002;97(5):671-78. https://doi.org/10.1002/ijc.10055 PMid:11807796 DOI: https://doi.org/10.1002/ijc.10055

Tsai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol. 2004;22(2):112-8. https://doi.org/10.1016/s1078-1439(03)00176-5 PMid:15082007 DOI: https://doi.org/10.1016/S1078-1439(03)00176-5

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-41. https://doi.org/10.1016/j.eururo.2012.07.033 PMid:22877502 DOI: https://doi.org/10.1016/j.eururo.2012.07.033

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscleinvasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801-9. https://doi.org/10.1200/jco.2014.57.5548 PMid:25366678 DOI: https://doi.org/10.1200/JCO.2014.57.5548

Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: Nonmuscle-invasive bladder cancer. BJU Int. 2017;119(3):371-80. https://doi.org/10.1111/bju.13760 PMid:28058776 DOI: https://doi.org/10.1111/bju.13760

Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, et al. Guideline of guidelines: Non-muscle-invasive bladder cancer. BJU Int. 2015;28:612-30.

Mitra AP. Molecular substratification of bladder cancer: Moving towards individualized patient management. Ther Adv Urol. 2016;8(3):215-33. PMid:27247631 DOI: https://doi.org/10.1177/1756287216638981

Frantzi M, Latosinska A, Fluhe L, Hupe MC, Critselis E, Kramer MW, et al. Developing proteomic biomarkers for bladder cancer: Towards clinical application. Nat Rev Urol. 2015;12(6):317-30. https://doi.org/10.1038/nrurol.2015.100 PMid:26032553 DOI: https://doi.org/10.1038/nrurol.2015.100

Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of amplification and overexpression of the c-myc oncogene in high grade breast cancer: FISH, in situ hybridization and immunohistochemical analysis. Br J Cancer. 2004;90(8):1612-19. https://doi.org/10.1038/sj.bjc.6601703 PMid:15083194 DOI: https://doi.org/10.1038/sj.bjc.6601703

Apple SK, Hecht JR, David W. Immunohistochemical evaluation of K-ras, P53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: Evidence for multistep carcinogenesis. Hum Pathol. 1999;30(2):123-30. https://doi.org/10.1016/s0046-8177(99)90265-4 PMid:10029438 DOI: https://doi.org/10.1016/S0046-8177(99)90265-4

Iraqi Cancer Registry 2012/Ministry of health/Iraq. Available from: https://www.bccru.uobaghdad.edu.iq. [Last accessed on 2021 Mar 14].

Daniel L. TNM staging: The common language for cancer care. Am Joint Committee Cancer. 2008.

Batool JJ. Al-heety: Immunohistochemical expression of caspase-3 and Bcl-2 in urinary bladder carcinoma. J Urol. 2010;4(5):42-74.

Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22(6):1007-13. https://doi.org/10.1200/jco.2004.05.174 PMid:14981105 DOI: https://doi.org/10.1200/JCO.2004.05.174

Lichtenstein AV, Potapova GI. Genetic defects as tumor markers. J Mol Biol. 2003;37(2):159-69. DOI: https://doi.org/10.1023/A:1023329201643

Favoni RE, De Cupis A. The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach. Natl Cancer Inst. 2000;52(2):179-206. PMid:10835099

Mazin J. Clinicopathological study of urinary bladder carcinoma by detection of the molecular marker p53 by in situ hybridization, before and after treatment. 2009;4:63-74.

Velthoven RV, Petein M, Osterlink W, Kiss R, Decaestecker C. Identification by quantitative chromatin pattern analysis of patients at risk for recurrence of superficial tranitional bladder carcinoma. J Urol. 2000;164(6):2134-37. https://doi.org/10.1016/s0022-5347(05)66984-4 PMid:11061942 DOI: https://doi.org/10.1016/S0022-5347(05)66984-4

Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-45. https://doi.org/10.1001/jama.2011.1142 PMid:21846855 DOI: https://doi.org/10.1001/jama.2011.1142

Rambau PF, Chalya PL, Jackson K. Schistosomiasis and urinary bladder cancer in North Western Tanzania: A retrospective review of 185 patients. Infect Agent Cancer. 2013;8(1):19. https://doi.org/10.1186/1750-9378-8-19 PMid:23705833 DOI: https://doi.org/10.1186/1750-9378-8-19

Vermeulen SH, Hanum N, Grotenhuis AJ, Castaño-Vinyals G, van der Heijden AG, Aben KK, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015;112(3):594-600. https://doi.org/10.1038/bjc.2014.601 PMid:25429525 DOI: https://doi.org/10.1038/bjc.2014.601

Machado MT, Pinto MA, Juliano RV, Mattos MH, Wroclawski ER. Alternatives for distal ureter resection in laparoscopic nephroureterectomy. Braz J Urol. 2002;28(2):109-15.

Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol. 2008;26(5):451-64. https://doi.org/10.1016/j. urolonc.2008.02.016 DOI: https://doi.org/10.1016/j.urolonc.2008.02.016

Chu H, Wang M, Zhang Z. Bladder cancer epidemiology and genetic susceptibility. J Biomed Res. 2013 May; 27(3):170-8. PMid:18562223

Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients. Urology. 1998;52(4):594-601. https://doi.org/10.1016/s0090-4295(98)00295-7 PMid:9763077 DOI: https://doi.org/10.1016/S0090-4295(98)00295-7

Al-Abassi D. IHC study of TCC of urinary bladder by application of VEGF in correlation to P53. BMC Res Notes. 2008;3:31-54.

Kadhim HS, Abdulamir AS, Hafidh RR, Abubaker F, Abbas KA. Investigations in the molecular events of transitional cell carcinoma of the bladder. Am J Biochem Biotechnol. 2008;4(4):408-15. https://doi.org/10.3844/ajbbsp.2008.408.415 DOI: https://doi.org/10.3844/ajbbsp.2008.408.415

Cheng L, Neumann RM, Weaver AL, Cheville JC, Leibovich BC, Ramnani DM, Scherer BG, et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Am J Clin Pathol. 2000;113(2):275-79. https://doi.org/10.1309/94b6-8vfb-mn9j-1nf5 PMid:10664630 DOI: https://doi.org/10.1309/94B6-8VFB-MN9J-1NF5

Nakanishi K, Kawai T, Aida S, Kasamatsu H, Aurues T, Ikeda T. Expression of p27Kip1 protein in transitional cell carcinoma of the upper urinary tract. Mod Pathol. 2001;14(5):371-76. PMid:11353044

Mohseni MG, Nourbakhsh A, Hatami ZN. Association of smoking with high-grade transitional cell carcinoma of the urinary bladder. Arch Iranian Med. 2005;8(4):286-9. https://doi.org/10.1038/modpathol.3880320 DOI: https://doi.org/10.1038/modpathol.3880320

Yang MH, Yen CC, Chen PM, Wang WS, Chang YH, Huang WJ, et al. Prognostic factors-based risk-stratification model for invasive urothelial carcinoma of the urinary bladder in Taiwan. Urology. 2002;59(2):232-38. https://doi.org/10.1016/s0090-4295(01)01590-4 PMid:11834392 DOI: https://doi.org/10.1016/S0090-4295(01)01590-4

Yossepowitch O, Dalbagni G. Transitional cell carcinoma of the bladder in young adults: Presentation, natural history, and outcome. J Urol. 2002;168(1):61-6. https://doi.org/10.1016/s0022-5347(05)64832-x PMid:12050493 DOI: https://doi.org/10.1016/S0022-5347(05)64832-X

Saxena S, Burra U, Varma S, Aggarwal A. Tripathi MJ. Role of in vitro Cytotoxicity Assessment and Immunologic Enhancement in the Management of Superficial Bladder Cancer. 2004;p20-22.

Stewart GD, Bariol SV, Grigor KM, Tolley DA, Mcneill SA. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. J Urol Int. 2005;95(6):791-93. https://doi.org/10.1111/j.1464-410x.2005.05402.x PMid:15794784 DOI: https://doi.org/10.1111/j.1464-410X.2005.05402.x

Wright C, Thomas D, Mellon K, Neal DE, Horne CH. Expression of retinoblastoma gene products and p53 protein in bladder carcinoma: Correlation with ki67 index. Br J Urol. 1995;75(2):173-9. https://doi.org/10.1111/j.1464-410x.1995.tb07306.x PMid:7850321 DOI: https://doi.org/10.1111/j.1464-410X.1995.tb07306.x

Cordon-Cardo C. Mutation of cell cycle regulators: Biological and clinical implications for human Neoplasia. Am J Pathol. 1995;147(3):545-60. PMid:7677168

Du J, Chen GG, Vlantis AC, Xu H, Tsang RK, van Hasselt AC. P53 in predicting recurrence and progression of urothelial cell carcinomas of urinary bladder. Korean J Urol. 2003;44:256-61.

Sarkis AS, Dalbagni G, Cordon-Cardo G, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell carcinoma of bladder: A marker for disease progression. J Natl Cancer Inst. 1993;85(1):53-9. https://doi.org/10.1093/jnci/85.1.53 PMid:7677935 DOI: https://doi.org/10.1093/jnci/85.1.53

Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani Farhang, Zhang Z, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome. Clin Cancer Res. 2002;8(1):171-9. PMid:11801555

Shariat SF, Takunaga H, Zhou JH, Kim JH, Ayala GE, Benedict WF, et al. P53, p21, pRB, and p16 Expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014-24. https://doi.org/10.1200/jco.2004.03.118 PMid:14981102 DOI: https://doi.org/10.1200/JCO.2004.03.118

Khaled HM, Bahnassy AA, Raafat AA, Zekri AN, Madboul MS, Mokhtar NM. Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer. BMC Cancer. 2009;9:32. https://doi.org/10.1186/1471-2407-9-32 PMid:19171060 DOI: https://doi.org/10.1186/1471-2407-9-32

Shiina H, Igawa M, Shigeno K. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology. 1999;56(3):239-47. https://doi.org/10.1159/000011971 PMid:10202280 DOI: https://doi.org/10.1159/000011971

Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation. J Clin Oncol. 2002;20(6):1544-50. https://doi.org/10.1200/jco.2002.20.6.1544 PMid:11896103 DOI: https://doi.org/10.1200/JCO.2002.20.6.1544

Camur NK, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int. 2002;52(7):463-69. https://doi.org/10.1046/j.1440-1827.2002.01371.x PMid:12167105 DOI: https://doi.org/10.1046/j.1440-1827.2002.01371.x

Liuxi C, Ying L, Qi Z, Mingming Z, Xuemeng H, Qiujie L, et al. p53/PCDH17/Beclin-1 proteins as prognostic predictors for urinary bladder cancer. J Cancer. 2019;10(25):6207-16. PMid:31772653 DOI: https://doi.org/10.7150/jca.37335